888results about "Ether/acetal active ingredients" patented technology

The invention belongs to the technical field of traditional Chinese medicine biology, and particularly relates to a pair of diastereoisomers in fresh bamboo juice as well as a preparation method and application of the diastereoisomers, in the diastereoisomers, a formula I is a dextroisomer and is named as (+)-fresh bamboo juice phenol A, and a formula II is a levoisomer and is named as (-)-fresh bamboo juice phenol A. According to the invention, a pair of diastereoisomer compounds (+)-fresh bamboo juice phenol A and (-)-fresh bamboo juice phenol A are successfully obtained from fresh bamboo juice, and an in-vitro cell test shows that the (+)-fresh bamboo juice phenol A has a remarkable inhibition effect on gastric cancer cells, liver cancer cells, colorectal cancer cells, bladder cancer cells and lung cancer cells of a human body; the compound can be used for preparing medicines for preventing or treating tumors, and has a wide application prospect.

The invention belongs to the technical field of pharmaceutical preparations, and relates to traditional Chinese medicine self-assembled nanoparticles for enhancing anti-inflammatory activity as well as a preparation method and application of the traditional Chinese medicine self-assembled nanoparticles. The traditional Chinese medicine self-assembled nanoparticles are prepared from biphenyl cyclooctene type lignan and an oleanane type pentacyclic triterpenoid compound, wherein the mass ratio of the biphenyl cyclooctene type lignan to the oleanane type pentacyclic triterpenoid compound is 1 to (0.125 to 8). Through an anti-solvent exchange method, the carrier-free nanoparticles based on self-assembly of the traditional Chinese medicine active ingredients are prepared by utilizing spontaneous non-covalent interaction between the biphenyl cyclooctene lignan and the oleanane pentacyclic triterpenoid, so that the cytotoxicity is remarkably reduced, the biocompatibility is enhanced, and the toxic and side effects are reduced; meanwhile, the traditional Chinese medicine self-assembled nano-particles have a remarkable cellular uptake effect, the absorption and utilization efficiency of the medicine is improved, and more efficient anti-inflammatory biological activity is shown.

The invention belongs to the technical field of traditional Chinese medicine biology, and particularly relates to a phenolic compound and a preparation method and application thereof.The phenolic compound is a pair of diastereoisomers, the formula I of the phenolic compound is dextroisomer and is named as (+)-fresh bamboo juice phenol B, and the formula II of the phenolic compound is levoisomer and is named as (-)-fresh bamboo juice phenol B. A pair of diastereoisomer phenolic compounds (+)-fresh bamboo juice phenol B and (-)-fresh bamboo juice phenol B are successfully obtained from fresh bamboo juice, and the diastereoisomer phenolic compounds (+)-fresh bamboo juice phenol B and (-)-fresh bamboo juice phenol B have remarkable inhibition effects on gastric cancer cells, liver cancer cells, colorectal cancer cells, bladder cancer cells and lung cancer cells of a human body through in-vitro cell tests; the compound can be used for preparing medicines for preventing or treating tumors, and has a wide application prospect.

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to a composition for resisting doxorubicin cardiotoxicity and a preparation method, application and a preparation thereof. The invention provides a composition capable of resisting doxorubicin cardiotoxicity, the composition comprises diosmetin and loureirin B, the diosmetin and the loureirin B can be extracted through natural plants, the raw materials are low in cost and easy to obtain, and clinical popularization and application are facilitated. The cell experiment research finds that the combined administration of diosmetin and loureirin B can significantly improve the survival rate of adriamycin-damaged myocardial cells and significantly reduce the active oxygen level and positive cell rate, and verifies the synergistic interaction of diosmetin and loureirin B in resisting adriamycin cardiotoxicity.

The invention discloses a triggering probiotic-drug conjugate and a preparation method and application thereof, and belongs to the technical field of oral drug delivery systems, the triggering probiotic-drug conjugate comprises probiotics, an adhesive inner layer formed by coordination of tannic acid and Fe < 3 + >, and an outer layer formed by pterostilbene-phospholipid bridged by ROS-responsive thioether bonds and cholesterol; the inner layer coats the surfaces of the probiotics through coordination, and the outer layer coats the outer part of the inner layer through self-assembly. An outer lipid layer is decomposed under high-concentration ROS in an inflammation colon area, and probiotics coated with pterostilbene and a tannic acid layer are released. Pterostilbene relieves inflammation and rebuilds a pathological microenvironment, and catechol groups in a tannic acid layer and the surface of the intestinal tract generate multiple interactions to promote planting of probiotics. In UC mouse models, the conjugates exhibit enhanced therapeutic effects by inhibiting inflammation, restoring intestinal barrier function, and improving intestinal microbiota homeostasis. The invention has important transformation potential in clinical application of gastrointestinal diseases.

Novel compositions and systems for closure of wounds with antimicrobial effectiveness provide devices of improved flexibility and elasticity and are readily applied to wound sites or over wound closure devices. A novel platinum catalyst comprising platinum tetramethyldivinyl disiloxane diethyl maleate complex for use in such compositions provides for rapid curing on topical surfaces such as skin and bonds to such surfaces in about 2-5 minutes.

The present specification discloses a means for suppressing a decrease in reduced coenzyme Q10 due to oxidation during the storage of a solid composition containing a co-crystal of reduced coenzyme Q10.　One or more embodiments of the present invention relate to a solid composition containing a co-crystal of reduced coenzyme Q10, an emulsifying agent, and an antioxidant. One or more other embodiments of the present invention relate to a method for producing a granular solid composition containing a co-crystal of reduced coenzyme Q10, an emulsifying agent, an antioxidant, and a binding agent, the method comprising granulating a mixture including the co-crystal of reduced coenzyme Q10, the emulsifying agent, the antioxidant, the binding agent, and a liquid binder.

The invention belongs to the field of medicine, and relates to application of polydocanol in preparation of medicine for treating bromhidrosis through dispersion gridding subcutaneous multipoint continuous injection application, the polydocanol is a polydocanol injection, and each milliliter of the injection contains 5-30 mg of polydocanol. The invention further provides a medicine for treating bromhidrosis through dispersion gridding subcutaneous multipoint continuous injection application. The medicine comprises polydocanol and pharmaceutically acceptable auxiliary materials. The invention has the advantages of small trauma, simplicity and convenience in operation, high safety, longer treatment effect maintenance time and the like, and the long-term relieving effective rate is greater than 80%.

A nutraceutical composition, consisting of Nicotinamide Mononucleotide in a range 250-1000 mg, Spermidine in a range 0.5-10 mg, Rhodiola Rosea in a range 200-600 mg, Cacao in a range 1000-10,000 mg, L-Theanine in a range 50-200 mg, Glucosamine in a range 500-3000 mg, and Hyaluronic acid in a range 50-240 mg, or consisting of Epigallocatechin-3-gallate in a range 100-500 mg, Quercetin in a range 250-1000 mg, Resveratrol in a range 150-1000 mg, Sulforaphane in a range 1-50 mg, and Calcium Alphaketoglutarate in a range 300-2000 mg, or consisting of Microdose Lithium in a range 1-5 mg, Trimethylglycine in a range 500-2000 mg, Glutathione in a range 250-1000 mg, Fisetin in a range 100-1000 mg, Urolithin A in a range 250-2000 mg, Sodium Butyrate in a range 100-3000 mg, Berberine in a range 500-1500 mg, Apigenin in a range 50-500 mg, Cinnamon in a range 1000-6000 mg, and Malate in a range 1000-6000 mg.

[Problem] To provide a novel ferroptosis-inducing drug, and in particular, to provide a ferroptosis induction promoter that can effectively promote the induction of ferroptosis even in a cell having ferroptosis resistance even in a ferroptosis-inducing environment (for example, cancer cells and senescent cells). [Solution] Provided is a ferroptosis induction promoter comprising a drug that can reduce lysosomal pH.

A powder mixture for oral delivery of active ingredients includes a population of particles and one or more active ingredients, the population of particles including at least two types of sugar alcohol particles. At least one of the at least two types of sugar alcohol particles takes the form of i) non-directly compressible (non-DC) sugar alcohol particles or ii) directly compressible (DC) sugar alcohol particles that are not granulated sugar alcohol particles. At least one of the at least two types of sugar alcohol particles has a particle size with more than 50% of the particles being below 250 microns, and at least one of the at least two types of sugar alcohol particles is present in an amount of at least 20% by weight of the powder mixture.

The invention relates to a phenylpropanoid compound as well as a preparation method and application thereof, in particular to a phenylpropanoid compound extracted from pleione bulbus pseudobulb as well as a preparation method and application thereof, and belongs to the technical field of medicines. The invention provides a method for preparing 10 new compounds from pleione bulbocodioides pseudobulb as a raw material for the first time, systematically evaluates the anti-neuroinflammation activity of pleione bulbocodioides pseudobulb, and clarifies the application of pleione bulbocodioides pseudobulb in development and treatment of central nervous system diseases. According to the invention, abnormally activated BV-2 microglial cells induced by LPS (Lipopolysaccharide) are adopted, and the NO release amount is taken as an index, so that the effect of the compound 1-10 on inhibiting excessive activation of the microglial cells is preliminarily evaluated. The result shows that the novel compounds 1-10 can inhibit the release of LPS-induced BV-2 microglial cell NO. Therefore, the compound prepared in the invention can be applied to development of drugs for treating central nervous system diseases.

The invention relates to the field of biological medicine, and discloses application of a biphenyl cyclooctene lignan compound and a chemotherapy sensitizing drug. The biphenyl cyclooctene lignan compound can be used for preparing a chemotherapy sensitizing drug, and the chemotherapy sensitizing drug is an ovarian cancer chemotherapy sensitizing drug, and can improve the sensitivity of cells to paclitaxel and inhibit the activity, proliferation and migration of the cells. The biphenyl cyclooctene lignan compound is combined with paclitaxel, so that the cell activity of the ovarian cancer paclitaxel drug-resistant cell A2780 / Taxol can be remarkably reduced, and the cell survival rate is only 31.13%. The combination of the biphenyl cyclooctene lignan compound and paclitaxel can also be used for preparing chemotherapy sensitizing drugs.

The invention relates to the technical field of functional antioxidants, in particular to a stability-enhanced antioxidant based on pterostilbene and a preparation method and application thereof. The pterostilbene tablet comprises the following components in percentage by weight: 10-30% of pterostilbene, 8-20% of Arabic gum, 5-15% of tocopheryl succinate, 1-5% of disodium ethylene diamine tetraacetate, 30-60% of beta-cyclodextrin, 2-8% of rosmarinic acid, 1-6% of chitosan quaternary ammonium salt, 0.5-3% of nano silicon dioxide and 2-7% of polyglycerol fatty acid ester. In the preparation process, beta-cyclodextrin and pterostilbene form an inclusion compound, the dispersity of nano silicon dioxide and chitosan quaternary ammonium salt is improved through hydrogen bonds, and tea polyphenol or ascorbyl palmitate can be added to enhance the synergistic effect. The antioxidant is high in stability, high in pterostilbene retention rate, uniform in dispersion, free of agglomeration, excellent in antioxidant activity, suitable for the fields of foods, cosmetics and medicines, simple in preparation process, low in consumption and suitable for industrial production.

The invention provides a reduced coenzyme Q10 eutectic crystal as well as a preparation method and application thereof. The eutectic crystal is prepared from the reduced coenzyme Q10 and L-lysine. Compared with the prior art, the prepared reduced coenzyme Q10 eutectic can effectively improve the stability of the reduced coenzyme Q10, and widens the solid existence form of the reduced coenzyme Q10. The preparation method of the reduced coenzyme Q10 eutectic crystal provided by the invention is simple, low in cost, convenient for large-scale production and favorable for subsequent product development, and particularly has important value for developing a reduced coenzyme Q10 solid oral preparation in the future.

A composition providing improved oral bioavailability of a drug and a method therefor. Also disclosed is the use of a delivery synergist in the improvement of the oral bioavailability of a protein or polypeptide drug. When the delivery synergist is added to the pharmaceutical composition at a certain ratio relative to a delivery agent, the delivery effect of the delivery agent can be maximized, which can not only reduce the use amount of the delivery agent, but can also improve the oral bioavailability of the drug.

The invention belongs to the technical field of traditional Chinese medicine biology, and particularly relates to application of a phenolic compound in preparation of a medicine for preventing or treating hepatic fibrosis. A pair of phenolic diastereoisomers (+)-fresh bamboo juice phenol C and (-)-fresh bamboo juice phenol C are separated from fresh bamboo juice, and an anti-hepatic fibrosis activity screening test shows that (+)-fresh bamboo juice phenol C has a remarkable inhibition effect on human hepatic stellate cells LX-2, has clinical application potential in anti-hepatic fibrosis treatment, and has broad application prospects. The method can be used for preparing medicines for preventing or treating hepatic fibrosis, and a new basis is provided for pharmacological research of fresh bamboo juice.

The invention belongs to the technical field of traditional Chinese medicine biology, and particularly relates to a phenolic diastereoisomer and a preparation method and application thereof.The phenolic diastereoisomer has the chemical structural formula shown in the formula I and the formula II, the formula I is dextroisomer and is named as (+)-fresh bamboo juice phenol D, and the formula II is levoisomer and is named as (-)-fresh bamboo juice phenol D. A pair of phenolic diastereoisomer compounds (+)-fresh bamboo juice phenol D and (-)-fresh bamboo juice phenol D are successfully obtained from fresh bamboo juice, and an anti-neurotoxicity activity test shows that (+)-fresh bamboo juice phenol D has a remarkable protection effect on PC12 cell injury caused by glutamic acid and can be used for preparing medicines for preventing or treating neurodegenerative diseases; wide application prospects are realized.

A formulation for oral administration comprises an expectorant, an analgesic, and at least one additional active ingredient having a modified release providing a therapeutic effect for each of the active ingredients for up to 12 hours.

The invention discloses an application of a pharmaceutical composition of erianin (ERI) and sorafenib (SOR) in preparation of an anti-liver cancer drug. The invention further discloses a pharmaceutical composition which comprises ERI and SOR, and the specific molar ratio of ERI to SOR is optimized and determined through an in-vitro experiment. The composition is developed based on multi-mode screening (network pharmacology prediction, molecular docking and molecular dynamics simulation) of STAT3 targets, and in-vitro experiments prove that the composition has synergistic anti-tumor activity and can be used for preparing anti-liver cancer drugs. The invention further discloses a development method of the ERI-SOR composition integrated with multi-mode computational simulation. Experiments prove that ERI and SOR both show a remarkable synergistic effect (combination index (CI) lt, 1) at the concentration of 0.5-16 [mu] M, CI at the optimal ratio (1: 1, 4 [mu] M + 4 [mu] M) reaches 0.617, the cell proliferation inhibition effect is remarkable compared with that of a single drug, and the excellent synergistic effect is shown.

Pharmaceutical compositions having enhanced active component permeation properties are described.

The invention discloses a traditional Chinese medicine composition for treating chronic obstructive pulmonary disease as well as a preparation and application thereof, and belongs to the technical field of chronic obstructive pulmonary disease medicines. The traditional Chinese medicine composition consists of a qi tonifying component, a blood activating component and a phlegm reducing component, or consists of the qi tonifying component and the blood activating component, or consists of the qi tonifying component and the phlegm reducing component, wherein the qi-tonifying component is selected from any one or a combination of more of ginsenoside Rg1, ginsenoside Rb1, astragaloside and schizandrin; the blood activating component is selected from any one or combination of more of ligustrazine and ferulic acid; the phlegm reducing component is selected from any one or combination of more of glucosinolate and quercetin. The compatibility and combination of the medicines have obvious effects in the aspects of improving lung inflammatory response and inhibiting pathological remodeling of pulmonary blood vessels.

Methods, compositions and uses for inhibiting the growth in blood cancer cells in a patient with one or more of a caffeic acid phenpropyl ester (GL8) analogue selected from the group consisting of As26, J229, J91, LL27, LL23, HM7, As25, MT26, and J205. The blood cancer cells can be myeloma, lymphoma and leukemia cells. The methods, compositions and uses can be in conjunction with the use of an IMiD to treat a patient. The compositions can include a pharmaceutically acceptable carrier, adjuvant or vehicle, a pharmaceutically acceptable salt or dietary supplement.

The present invention relates to an antimicrobial and healing formulation for skin, designed to effectively target and treat skin conditions such as acne caused by Cutibacterium acnes, cold sore lesions due to the herpes simplex virus, and superficial wounds. This unique formulation combines antimicrobial agents, plant extracts and essential oils in specific proportions in order to exert a synergistic action, enhancing their individual efficacy in the treatment of skin conditions and promoting skin healing. The innovative formulation composed of niaouli (Melaleuca viridiflora) essential oil and tea tree (Melaleuca alternifolia) essential oil, chlorhexidine digluconate, Hamamelis virginiana extract, panthenol, glycerol, and propylene glycol. Each ingredient has been selected for its proven pharmacological properties and its synergistic potential. The formulation works in concert to reduce microbial load, alleviate inflammation, and accelerate skin healing, while providing a gentle and effective application.

The invention discloses a composition capable of improving oral bioavailability of drugs and a method thereof, and further discloses application of a delivery synergist in improving oral bioavailability of protein or polypeptide drugs. After the delivery synergist is added into the pharmaceutical composition provided by the invention, the delivery effect of a delivery agent can be exerted to the greatest extent under a certain proportion of the delivery synergist and the delivery agent, so that not only can the use amount of the delivery agent be reduced, but also the oral bioavailability of the medicine can be increased.

The invention belongs to the technical field of external pharmaceutical compositions, and particularly relates to a temperature phase change microsphere antibacterial gel and a preparation method thereof. The gel is composed of three core components: temperature phase change microspheres, a composite antibacterial component and a carbomer matrix solution. The antibacterial component comprises carvacrol, oregano oil, cinnamyl aldehyde, citral, gallic acid and nano-silver, and aims to realize a broad-spectrum and efficient antibacterial effect. Hydrogel is prepared into microspheres (the phase change temperature is 33 DEG C) by utilizing a micro-fluidic chip technology, antibacterial components are wrapped in the microspheres, and then the temperature phase change microsphere antibacterial gel is compounded. When the gel is daily stored, the microspheres can realize long-time activity maintenance of antibacterial components and play a role in protecting the active components. When the gel is smeared on the skin surface, the human body temperature (36-37 DEG C) is higher than the phase change temperature (33 DEG C), the gel microspheres are subjected to phase change, sustained and controlled release of antibacterial components is achieved, and the better antibacterial effect is achieved.

A flowpack for oral delivery of active ingredients comprises a population of particles and one or more active ingredients, the population of particles including at least two types of sugar alcohol particles, wherein at least one of said two types of sugar alcohol particles comprises granulated sugar alcohol particles.

The invention discloses application of apigenin in preparation of a product for treating sjogren syndrome, and belongs to the technical field of medicines. The apigenin is used for remarkably regulating and controlling the immune system of the body, namely enhancing the immunosuppression function of MDSCs of the body, further inhibiting activation of dendritic cells DCs, resulting in reduction of the expression level of B cell activating factors BAFF, finally achieving the purposes of inhibiting B cell differentiation and reducing immunocompetence, and relieving the symptoms of SS.

The present invention provides compounds that are useful as modulators of the cannabinoid receptor 2 (CB2R) having the general formula (I), wherein R1 to R3 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.

The present disclosure provides for the use of compounds of Formula I in lipid micro- and nanoparticle compositions. The present disclosure also extends to micro- or nanoparticles comprising a compound of Formula I and an optional payload molecule, and medical uses thereof.